Literature DB >> 17123284

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Richard B Freeman1, Robert G Gish, Ann Harper, Gary L Davis, John Vierling, Leslie Lieblein, Goran Klintmalm, Jamie Blazek, Robert Hunter, Jeffrey Punch.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17123284     DOI： 10.1002/lt.20979

Source DB:  PubMed          Journal:  Liver Transpl        ISSN： 1527-6465            Impact factor:   5.799


× No keyword cloud information.
  35 in total

1.  Center differences in model for end-stage liver disease exceptions: fairness, local culture, and norms of practice.

Authors:  Michael L Volk
Journal:  Liver Transpl       Date:  2013-10-10       Impact factor: 5.799

2.  Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.

Authors:  Julie K Heimbach; Ryutaro Hirose; Peter G Stock; David P Schladt; Hui Xiong; Jiannong Liu; Kim M Olthoff; Ann Harper; Jon J Snyder; Ajay K Israni; Bertram L Kasiske; W Ray Kim
Journal:  Hepatology       Date:  2015-02-24       Impact factor: 17.425

Review 3.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

4.  Barriers to transplantation in adults with inborn errors of metabolism.

Authors:  S M Sirrs; H Faghfoury; E M Yoshida; T Geberhiwot
Journal:  JIMD Rep       Date:  2012-08-22

5.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 6.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

7.  Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.

Authors:  David S Goldberg; Karen Krok; Sachin Batra; James F Trotter; Steven M Kawut; Michael B Fallon
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

8.  Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.

Authors:  Reena J Salgia; Nathan P Goodrich; Heather Simpson; Robert M Merion; Pratima Sharma
Journal:  Dig Dis Sci       Date:  2014-02-21       Impact factor: 3.199

9.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Authors:  Eric C Ehman; Spencer C Behr; Sarah E Umetsu; Nicholas Fidelman; Ben M Yeh; Linda D Ferrell; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 10.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.